Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/168625
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients |
Autor: | Paiva, Bruno; Cedena, Maria-Teresa; Puig, Noemi; Arana, Paula; Vidriales, Maria Belén; Cordón, Lourdes; Flores-Montero, Juan; Gutiérrez, Norma Carmen; Martín-Ramos, María-Luisa; Martínez-López, Joaquín; Ocio, Enrique M. CSIC ORCID ; Hernandez, Miguel T.; Teruel, Ana-Isabel; Rosiñol, Laura; Echeveste, María-Asunción; Martínez, Rafael; Gironella, Mercedes; Oriol, Albert; Cabrera, Carmen; Martín, Jesús; Bargay, Joan; Encinas, Cristina; González, Yolanda; Dongen, J. J. M. van; Orfao, Alberto CSIC ORCID ; Bladé, Joan; Mateos, Maria Victoria; Lahuerta, Juan José; San Miguel, Jesús F. CSIC ORCID | Fecha de publicación: | 2016 | Editor: | American Society of Hematology | Citación: | Blood 127(25): 3165-3174 (2016) | Resumen: | The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients. Because an optimal balance between treatment efficacy and toxicity is of utmost importance in patients with elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used second-generation 8-color multiparameter-flow cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from first- to second-generation MFC resulted in increased sensitivity and allowed us to identify 3 patient groups according to MRD levels: MRD negative (<10; n = 54, 34%), MRD positive (between <10 and ≥10; n = 20, 12%), and MRD positive (≥10; n = 88, 54%). MRD status was an independent prognostic factor for time to progression (TTP) (hazard ratio [HR], 2.7; P = .007) and overall survival (OS) (HR, 3.1; P = .04), with significant benefit for MRD-negative patients (median TTP not reached, 70% OS at 3 years), and similar poorer outcomes for cases with MRD levels between <10 and ≥10 vs ≥10 (both with a median TTP of 15 months; 63% and 55% OS at 3 years, respectively). Furthermore, MRD negativity significantly improved TTP of patients >75 years (HR, 4.8; P < .001), as well as those with high-risk cytogenetics (HR, 12.6; P = .01). Using second-generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate, and favorable outcomes (25%, 61%, and 100% OS at 3 years, respectively; P = .01), the later patients being characterized by an increased compartment of mature B cells. Our results show that similarly to transplant candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM patients, irrespectively of age or cytogenetic risk. | URI: | http://hdl.handle.net/10261/168625 | DOI: | 10.1182/blood-2016-03-705319 | Identificadores: | doi: 10.1182/blood-2016-03-705319 e-issn: 1528-0020 issn: 0006-4971 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
66
checked on 10-abr-2024
SCOPUSTM
Citations
133
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
122
checked on 27-feb-2024
Page view(s)
367
checked on 22-abr-2024
Download(s)
82
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.